Twenty patients with DDLPS were enrolled in a neoadjuvant biopsy-driven biomarker study investigating the impact of the MDM2 antagonist RG7112 on the p53 pathway and proliferation through sequential biopsies [10]. Here, MDM2 is linked to dedifferentiated liposarcoma.